Epivir and Bone loss - a phase IV clinical study of FDA data

Summary:

Bone loss is reported as a side effect among people who take Epivir (lamivudine), especially for people who are male, 50-59 old, have been taking the drug for 5 - 10 years also take Truvada, and have Hepatitis b.

The phase IV clinical study analyzes which people have Bone loss when taking Epivir. It is created by eHealthMe based on reports of 16,823 people who have side effects when taking Epivir from the FDA, and is updated regularly.

What is Epivir?

Epivir has active ingredients of lamivudine. It is often used in hiv infection. eHealthMe is studying from 16,870 Epivir users. Check the latest studies of Epivir.

What is Bone loss?

Bone loss is found to be associated with 695 drugs and 557 conditions by eHealthMe. Check the latest studies of Bone loss.

On Jul, 18, 2026

16,823 people reported to have side effects when taking Epivir.
Among them, 108 people (0.64%) have Bone loss.

Among these 108 people:

* Approximation only. Some reports may have incomplete information.

Do you take Epivir and have Bone loss?

- Check whether Bone loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epivir:

Epivir (16,870 reports)

Bone loss treatments and more:

Bone loss (27,142 reports)

How severe was Bone loss and when was it recovered:

Bone loss in Epivir

Expand to all the drugs that have ingredients of lamivudine:

Bone loss and drugs with ingredients of lamivudine

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Epivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone loss:

Bone loss (695 drugs)

Browse all the conditions that are associated with Bone loss:

Bone loss (557 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine (the active ingredients of Epivir) and Epivir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.